Search Result

Results for "

USP7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Autophagy (2) Deubiquitinase (28) IKK (1) MDM-2/p53 (2) NF-κB (1) PROTACs (2) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (29) Inflammation/Immunology (1) Metabolic Disease (1)

Inhibitors & Agonists

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134817

USP7-IN-8	Deubiquitinase	Cancer
USP7-IN-8 (example 81) is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC₅₀ of 1.4 μM in an Ub-Rho110 assay. USP7-IN-8 shows no activity against USP47 and USP5. USP7-IN-8 has anticancer effects .

HY-148482

USP7-IN-11	Deubiquitinase	Cancer
USP7-IN-11 is a potent ubiquitin-specific protease 7 (USP7) (Deubiquitinase) inhibitor with an IC₅₀ of 0.37 nM. USP7-IN-11 has anticancer effects (WO2022048498A1; Example 187) .

HY-RS15568

USP7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
USP7 Human Pre-designed siRNA Set A contains three designed siRNAs for USP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

USP7 Human Pre-designed siRNA Set A USP7 Human Pre-designed siRNA Set A

HY-148481

USP7-IN-10

Deubiquitinase Cancer

USP7-IN-10 (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC₅₀ of 13.39 nM .
HY-153942

USP7-IN-12

Deubiquitinase Cancer

USP7-IN-12 (compound 1) is a potent and orally active Usp7 inhibitor with an IC₅₀ value of 3.67 nM. USP7-IN-12 shows antiproliferative activity .

USP7-IN-10	Deubiquitinase	Cancer
USP7-IN-10 (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC₅₀ of 13.39 nM .

USP7-IN-12	Deubiquitinase	Cancer
USP7-IN-12 (compound 1) is a potent and orally active *Usp7* inhibitor with an IC₅₀ value of 3.67 nM. USP7-IN-12 shows antiproliferative activity .

HY-136910

USP7-IN-7	Deubiquitinase	Cancer
USP7-IN-7 (compound 124) is a *USP7* inhibitor with an IC₅₀ value ＜10 nM. USP7-IN-7 shows cytotoxicity against p53-mutant cancer cell lines, p53 wild-type blood cancer and neuroblastoma cell lines with low nanomolar values. USP7-IN-7 can be used for cancer research .

HY-112128

USP7-IN-3

Deubiquitinase Cancer

USP7-IN-3 (Compound 5) is a potent and selective allosteric ubiquitin-specific protease 7 (USP7) inhibitor .
HY-148481A

USP7-IN-10 hydrochloride

Deubiquitinase Cancer

USP7-IN-10 hydrochloride (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC₅₀ of 13.39 nM .

USP7-IN-3	Deubiquitinase	Cancer
USP7-IN-3 (Compound 5) is a potent and selective allosteric ubiquitin-specific protease 7 (USP7) inhibitor .

USP7-IN-10 hydrochloride	Deubiquitinase	Cancer
USP7-IN-10 hydrochloride (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC₅₀ of 13.39 nM .

HY-16709

USP7-IN-1 4 Publications Verification	Deubiquitinase	Cancer
USP7-IN-1 is a selective and reversible inhibitor of ubiquitin-specific protease 7 (USP7), with an IC₅₀ of 77 μM, and can be used for the research of cancer.

HY-160515

USP7-IN-13

Deubiquitinase Cancer

USP7-IN-13 (Compound 101) is a USP7 inhibitor with an IC₅₀ value of 0.2-1 μM, which can be used for the study of multiple myeloma .

USP7-IN-13	Deubiquitinase	Cancer
USP7-IN-13 (Compound 101) is a *USP7* inhibitor with an IC₅₀ value of 0.2-1 μM, which can be used for the study of multiple myeloma .

HY-146887

USP7-IN-9	Deubiquitinase Apoptosis	Cancer
USP7-IN-9 is a highly potent ubiquitin-specific protease 7 (USP7) inhibitor with an IC₅₀ value of 40.8 nM. USP7-IN-9 can induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21 .

HY-129169

USP7-IN-6

Deubiquitinase Cancer

USP7-IN-6 is a potent ubiquitin specific protease 7 (USP7) inhibitor, extracted from patent WO2017212010A1, example 25, has an IC₅₀ of 6.8 nM .

USP7-IN-6	Deubiquitinase	Cancer
USP7-IN-6 is a potent ubiquitin specific protease 7 (USP7) inhibitor, extracted from patent WO2017212010A1, example 25, has an IC₅₀ of 6.8 nM .

HY-13487

USP7/USP47 inhibitor 3 Publications Verification	Deubiquitinase	Cancer
USP7/USP47 inhibitor is a selective ubiquitin-specific protease 7/47 (USP7/USP47) inhibitor, with EC₅₀s of 0.42 μM and 1.0 μM, respectively.

HY-138794

XL177A	Deubiquitinase	Cancer
XL177A is a highly potent and selective irreversible *USP7* inhibitor with an IC₅₀ of 0.34 nM. XL177A elicits cancer cell killing through a p53-dependent mechanism .

HY-160502

CST967	PROTACs	Cancer
CST967 (Compound 17) is a USP7 PROTAC degrader, and increasing the PROTAC concentration can enhance the degradation rate of USP7. CST967 can be used in cancer research .

HY-122886

XL 188	Deubiquitinase	Cancer
XL 188 is a potent and selective *USP7* inhibitor with IC₅₀ values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer .

HY-112937

GNE-6640 2 Publications Verification	Deubiquitinase	Cancer
GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 *(USP7), with IC₅₀* values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP43 and Ub-MDM2, respectively .

HY-101666

HBX 41108 1 Publications Verification	Deubiquitinase Apoptosis MDM-2/p53	Metabolic Disease Cancer
HBX 41108 is an inhibitor of ubiquitin-specific protease 7 (USP7) with an IC₅₀ of 424 nM. HBX 41108 inhibits USP7-mediated p53 deubiquitination to stabilize p53 and inhibits cancer cell growth. BX 41108 can be used in cancer and diabetes research .

HY-107986

GNE-6776

2 Publications Verification

Deubiquitinase Cancer

GNE-6776 is a selective and orally bioavailable USP7 inhibitor .
HY-15667

P005091

10+ Cited Publications

P5091
Deubiquitinase Cancer

P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC₅₀ of 4.2 μM.
HY-17540

HBX 19818

10+ Cited Publications

Deubiquitinase Cancer

HBX 19818 is a specific inhibitor of ubiquitin-specific protease 7 (USP7), with an IC₅₀ of 28.1 μM.

GNE-6776 2 Publications Verification	Deubiquitinase	Cancer
GNE-6776 is a selective and orally bioavailable *USP7* inhibitor .

P005091 10+ Cited Publications P5091	Deubiquitinase	Cancer
P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC₅₀ of 4.2 μM.

HBX 19818 10+ Cited Publications	Deubiquitinase	Cancer
HBX 19818 is a specific inhibitor of ubiquitin-specific protease 7 (USP7), with an IC₅₀ of 28.1 μM.

HY-158039

YCH2823	Deubiquitinase Apoptosis	Cancer
YCH2823 is an inhibitor of *USP7* (IC₅₀ = 49.6 nM; K_d = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors .

HY-13865

P 22077 10+ Cited Publications	Deubiquitinase	Cancer
P 22077 is a cell-permeable ubiquitin-specific protease 7 (USP7) inhibitor with an EC₅₀ of 8.01 μM. P 22077 also inhibits USP47 with an EC₅₀ of 8.74 μM.

HY-100708

NSC632839 3 Publications Verification	Deubiquitinase	Cancer
NSC632839 is a nonselective isopeptidase inhibitor, which inhibits *USP2, USP7, and SENP2* with EC₅₀s of 45±4 μM, 37±1 μM, and 9.8±1.8 μM, respectively.

HY-13814

PR-619 10+ Cited Publications	Deubiquitinase Autophagy Apoptosis	Cancer
PR-619 is a broad-range and reversible DUB inhibitor with EC₅₀s of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for *USP4, USP8, USP7, USP2, and USP5*, respectively. PR-619 induces ER Stress and ER-Stress related apoptosis .

HY-149228

USP28-IN-2	Deubiquitinase	Cancer
USP28-IN-2 is a *USP28* inhibitor (IC₅₀=0.3 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-2 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-2 also decreases the ankyrase-1/2 level in vitro. USP28-IN-2 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .

HY-149229

USP28-IN-3	Deubiquitinase	Cancer
USP28-IN-3 is a *USP28* inhibitor (IC₅₀=0.1 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-3 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-3 also decreases the ankyrase-1/2 level in vitro. USP28-IN-3 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .

HY-149230

USP28-IN-4	Deubiquitinase	Cancer
USP28-IN-4 is a *USP28* inhibitor (IC₅₀=0.04 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-4 also decreases the ankyrase-1/2 level in vitro. USP28-IN-4 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .

HY-148369

U7D-1	PROTACs Deubiquitinase Apoptosis MDM-2/p53	Cancer
U7D-1 is a first-in-class potent and selective *USP7* (ubiquitin-specific protease 7) PROTAC degrader, with a DC₅₀ of 33 nM in RS4;11 cells. U7D-1 shows anticancer activity. U7D-1 induces apoptosis in Jeko-1 cells .

HY-13453

BAY 11-7082 Maximum Cited Publications 267 Publications Verification BAY 11-7821	IKK Deubiquitinase Autophagy Apoptosis NF-κB	Inflammation/Immunology Cancer
BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease *USP7* and *USP21* (IC₅₀=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .

Species:	Human (3)
Tag:	His (1) Tag Free (2)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P702603

USP7 Protein, Human (His)

Ubiquitin carboxyl-terminal hydrolase 7; USP7; HAUSP
Human E. coli

HY-P74478

	USP7 Protein, Human (sf9) Ubiquitin carboxyl-terminal hydrolase 7; USP7; HAUSP	Human	Sf9 insect cells
	The USP7 protein is a hydrolase that deubiquitinates multiple targets, including FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5, and DAXX. It cooperates with DAXX to enhance the E3 ligase activity of MDM2 and promote ubiquitination and degradation of p53/TP53. USP7 Protein, Human (sf9) is the recombinant human-derived USP7 protein, expressed by Sf9 insect cells , with tag free. The total length of USP7 Protein, Human (sf9) is 353 a.a., with molecular weight of ~41 kDa.

HY-P702604

USP7 Protein, Human

Ubiquitin carboxyl-terminal hydrolase 7; USP7; HAUSP
Human E. coli


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

USP7 Antibody (YA657) Deubiquitinating enzyme 7; HAUSP; herpes virus associated; Herpes virus associated ubiquitin specific protease; Herpesvirus-associated ubiquitin-specific protease; TEF 1; tef-1; TEF1; Ubiquitin carboxyl terminal hydrolase 7; Ubiquitin carboxyl-terminal hy	WB	Human
USP7 Antibody (YA657) is a non-conjugated and Mouse origined monoclonal antibody about 128 kDa, targeting to USP7 (3E4). It can be used for WB assays with tag free, in the background of Human.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: